Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Israel plunges into political turmoil over Benjamin Netanyahu’s judicial reforms
    • Israel protests intensify after Netanyahu sacks defence minister
    • China’s economic rebound weaker than expected, warns Maersk
    • Italy seizes Banksy-funded rescue ship as migrant crossings surge
    • Vladimir Putin plans to deploy tactical nuclear weapons in Belarus
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Banks in turmoil
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • European ammunition maker says plant expansion hit by energy-guzzling TikTok site
      • First Citizens to buy failed Silicon Valley Bank
      • Saudi National Bank chair resigns following Credit Suisse comments
      • Air India boss hails biggest turnround effort in airline’s history
      • Wine growers fear funding will wither after fall of Silicon Valley Bank
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Money market funds swell by more than $286bn as investors pull deposits from banks
      • Live news: US derivatives regulator sues Binance and founder Changpeng Zhao
      • Russia embraces China’s renminbi in face of western sanctions
      • Jay Powell and Janet Yellen struggle to calm nerves in banking crisis
      • Hedge funds scale back bets against Scottish Mortgage
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • A new technology boom is at hand
      • Credit Suisse’s demise: a new twist on the ‘Swiss finish’
      • Why five days in the office don’t add up
      • The unstoppable rise of government rescues
      • Japan remains free from the tyranny of tipping
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Matthew Desmond: ‘America does so much more to subsidise affluence than alleviate poverty’
      • Culture clash: the challenge of uniting fierce rivals UBS and Credit Suisse
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Everything I, an Italian, thought I knew about Italian food is wrong
      • My life with Ozempic – a weight-loss diary
      • To Istanbul, by train
      • Is France on the road to a Sixth Republic?
      • Perfectly peaceful Puglian retreats
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Moderna

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Tuesday, 14 March, 2023
      Covid-19 vaccines
      Pfizer’s revised EU Covid vaccine contract meets resistance

      Four member states including Poland say amended deal is not ‘fair solution’ to surplus of shots

    • Monday, 2 January, 2023
      LexDrugs research
      Moderna/BioNTech: cancer vaccines will show mRNA not a one-trick pony Premium content

      Success in battle against Covid does not ensure success against tumours, but should narrow the odds

    • Tuesday, 13 December, 2022
      Drugs research
      Moderna’s mRNA cancer vaccine shows promise in early trial

      Study suggests combination with Merck immunotherapy drug reduces risk of death in high-risk patients

    • Tuesday, 8 November, 2022
      Covid-19 vaccines
      Patent wars: Moderna’s battle for the spoils of Covid vaccines

      Ending of pharma group’s IP truce spells fight for future of mRNA technology

    • Thursday, 3 November, 2022
      Moderna cuts Covid vaccine sales forecast

      Jab maker ties weaker revenue outlook to delivery delays and manufacturing issues

    • Sunday, 16 October, 2022
      Covid-19 vaccines
      Vaccine makers face revenue slump as demand falls for Covid jabs

      Pharmaceutical companies hunt for new revenue streams as coronavirus becomes endemic

    • Thursday, 13 October, 2022
      InterviewCovid-19 vaccines
      Beijing’s failure to import mRNA Covid jabs ‘mind-boggling’, says BeiGene executive

      Chinese biotech’s research chief calls decision ‘unfortunate’ as zero-Covid policy strangles economy

    • Saturday, 1 October, 2022
      Moderna refused China request to reveal vaccine technology

      Pharma company still ‘eager’ to collaborate with Beijing, despite collapse of initial talks

    • Wednesday, 28 September, 2022
      Behind the Money podcast18 min listen
      Who will pay for the next Covid vaccines?

      Experts are concerned that the US isn’t doing enough to support the development of the next wave of vaccines and treatments that the world needs to fight the Covid-19 pandemic

    • Wednesday, 31 August, 2022
      Covid-19 vaccines
      US approves Omicron vaccines from Moderna and BioNTech/Pfizer

      FDA clears jabs despite lack of human trials in effort to curb winter wave of Covid infections

    • Friday, 26 August, 2022
      Covid-19 vaccines
      Moderna accuses BioNTech/Pfizer of copying mRNA technology

      US biotech claims rival Covid vaccine makers infringed patents underpinning jabs developed to combat the pandemic

    • Monday, 15 August, 2022
      Covid-19 vaccines
      UK becomes first country to approve Omicron-specific Covid booster

      Moderna’s two-strain shot will target both the original strain and BA.1 in step with European regulators

    • Sunday, 10 July, 2022
      FT SeriesLeading in a crisis
      Moderna’s Noubar Afeyan on the race to create a Covid vaccine

      The chair of the $60bn US biopharma group explains how his approach to combining science with entrepreneurship led to the company’s creation

    • Wednesday, 22 June, 2022
      Moderna calls for approval of two-strain Covid vaccine booster

      US biotech group says shot targeting both first strain and Omicron could help avert ‘large rise’ in cases

    • Wednesday, 22 June, 2022
      Covid-19 vaccines
      UK signs £1bn deal with Moderna for new vaccine centre

      Government seeks to secure domestic jab supply and prepare for future pandemics in deal with Boston biotech

    • Wednesday, 15 June, 2022
      Covid-19 vaccines
      FDA advisory panel backs Covid-19 vaccines for children under 5

      US prepares to roll out jabs to last age group without access once regulatory approval is received

    • Wednesday, 8 June, 2022
      Covid-19 vaccines
      Moderna reports positive data for new Covid booster targeting Omicron variant

      US pharma company aims to roll out the new vaccine by late summer

    • Wednesday, 18 May, 2022
      Interview
      Moderna chair defends executive hiring process after CFO fiasco

      Top finance director ousted after one day in job following emergence of probe at former employer

    • Saturday, 14 May, 2022
      News in-depth
      Moderna CFO’s departure reignites debate over company’s culture

      Exit of Jorge Gomez after only a day in the job is latest in string of executives to leave biotech group

    • Wednesday, 11 May, 2022
      Moderna’s new CFO departs in first week in job

      Jorge Gomez leaves vaccine maker after former employer launches probe into financial reporting

    • Wednesday, 4 May, 2022
      Moderna targets autumn release for Omicron vaccine

      US drugmaker says demand for ‘bivalent booster’ could lift jab sales in second half of 2022

    • Wednesday, 27 April, 2022
      Moderna investors reject proposal to transfer vaccine tech

      Two top-10 shareholders say distribution problems not supply is reason for slower vaccination rates in low-income countries

    • Friday, 22 April, 2022
      The Top LineTom Braithwaite
      ‘We are drowning in vaccine.’ What will revive the market for Covid jabs?

      Moderna’s chief says there is ‘massive oversupply’

    • Tuesday, 19 April, 2022
      Covid-19 vaccines
      Moderna and Pfizer urged to share vaccine technology with developing world

      Proxy advisers back shareholder resolutions as new shot shows promising results

    • Tuesday, 5 April, 2022
      Pfizer Inc
      Chief executives of mRNA vaccine groups earned $100mn in pandemic pay

      Remuneration at the three big jab makers reflects surge in value of share options

    Previous page You are on page 1 Next page

    Be part of FT Community

    Discover unmissable flagship events and members only communities to expand your thinking and elevate your career

    FT Live
    US Pharma and Biotech Summit
    Leading Life Sciences into the Future
    Tuesday, 16th MayNew York, US & Online
    Learn more about FT Community

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Banks in turmoil
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In